相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In Vivo Fluorescence Imaging of Passive Inflammation Site Accumulation of Liposomes via Intravenous Administration Focused on Their Surface Charge and PEG Modification
Hisako Ibaraki et al.
PHARMACEUTICS (2021)
Platelet count evaluation compared with the immunoplatelet reference method and performance evaluation of the hematology analyzer Celltac G
Kenji Yamade et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
The rediscovery of platinum-based cancer therapy
Sven Rottenberg et al.
NATURE REVIEWS CANCER (2021)
Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
Simona D'Aguanno et al.
CELLS (2020)
Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems
Maria Grazia Ferraro et al.
CELLS (2020)
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Claudia Pellacani et al.
ADVANCES IN MEDICAL SCIENCES (2020)
Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives
Sang Yeul Lee et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Joy X. Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication
Yong-Moon Lee et al.
GENES & GENOMICS (2020)
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio et al.
MOLECULES (2019)
Targeting BAX to drug death directly
Loren D. Walensky
NATURE CHEMICAL BIOLOGY (2019)
Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
Marialuisa Piccolo et al.
SCIENTIFIC REPORTS (2019)
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Luyu Qi et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433
Susan Monro et al.
CHEMICAL REVIEWS (2019)
The reduction of ruthenium(III) complexes with triazolopyrimidine ligands by ascorbic acid and mechanistic insight into their action in anticancer therapy
Joanna Wisniewska et al.
INORGANICA CHIMICA ACTA (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity
Claudia Riccardi et al.
PHARMACEUTICALS (2019)
Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
Steve P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Design of Ru-arene Complexes for Antitumor Drugs
Wei Su et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2018)
AS1411-decorated niosomes as effective nanocarriers for Ru(III)-based drugs in anticancer strategies
Claudia Riccardi et al.
JOURNAL OF MATERIALS CHEMISTRY B (2018)
Safety of novel liposomal drugs for cancer treatment: Advances and prospects
Keyu He et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2018)
RuIII Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic
Claudia Riccardi et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2017)
Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors
Prakash Thangavel et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Recent development of transition metal complexes with in vivo antitumor activity
Jia-Xin Liang et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2017)
Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action
Carlo Irace et al.
SCIENTIFIC REPORTS (2017)
The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
Leli Zeng et al.
CHEMICAL SOCIETY REVIEWS (2017)
Platinum-induced neurotoxicity: A review of possible mechanisms
Ozkan Kanat et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines
Lea S. Flocke et al.
INVESTIGATIONAL NEW DRUGS (2016)
Lipooligosaccharides as Amphiphiles to Build Liposomes for Effective Drug Delivery: The Case of Anticancer Ruthenium Complex-Based Aggregates
Federica Acampora et al.
CHEMISTRYSELECT (2016)
Athymic Nude Mice as an Experimental Model for Cancer Treatment
I. Szadvari et al.
PHYSIOLOGICAL RESEARCH (2016)
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in- human, open-label, dose-escalation phase I study with expansion cohort
Howard A. Burris et al.
ESMO OPEN (2016)
Cationic liposomes evoke proinflammatory mediator release and neutrophil extracellular traps (NETs) toward human neutrophils
Tsong-Long Hwang et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2015)
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery
Franco M. Muggia et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A ruthenium(II) complex inhibits tumor growth in vivo with fewer side-effects compared with cisplatin
Jin-Quan Wang et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2015)
In vivo toxicity of cationic micelles and liposomes
Kristina Bram Knudsen et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex
Giuseppe Vitiello et al.
JOURNAL OF MATERIALS CHEMISTRY B (2015)
Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer
Sebastian Strieth et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
In Vitro and in Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer
Malgorzata Frik et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(η6-p-cymene)-Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas
Andrea Weiss et al.
CHEMICAL SCIENCE (2014)
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl et al.
CHEMICAL SCIENCE (2014)
Enhanced localization of anticancer drug in tumor tissue using polyethylenimine-conjugated cationic liposomes
Hee Dong Han et al.
NANOSCALE RESEARCH LETTERS (2014)
Anticancer Cationic Ruthenium Nanovectors: From Rational Molecular Design to Cellular Uptake and Bioactivity
Gaetano Mangiapia et al.
BIOMACROMOLECULES (2013)
A new design for nucleolipid-based Ru(III) complexes as anticancer agents
Daniela Montesarchio et al.
DALTON TRANSACTIONS (2013)
Cytotoxicity of Cationic Liposomes Coated by N-Trimethyl Chitosan and Their In Vivo Tumor Angiogenesis Targeting Containing Doxorubicin
Xian-Xi Guo et al.
JOURNAL OF APPLIED POLYMER SCIENCE (2013)
Cholesterol-Based Nucleolipid-Ruthenium Complex Stabilized by Lipid Aggregates for Antineoplastic Therapy
Luca Simeone et al.
BIOCONJUGATE CHEMISTRY (2012)
Ruthenium-based complex nanocarriers for cancer therapy
Gaetano Mangiapia et al.
BIOMATERIALS (2012)
Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines
Maria Coimbra et al.
JOURNAL OF CONTROLLED RELEASE (2012)
NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
Robert Trondl et al.
BMC Pharmacology & Toxicology (2012)
Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
Patrycja Nowak-Sliwinska et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Nucleolipid nanovectors as molecular carriers for potential applications in drug delivery
Luca Simeone et al.
MOLECULAR BIOSYSTEMS (2011)
Choosing the right cell line for breast cancer research
Deborah L. Holliday et al.
BREAST CANCER RESEARCH (2011)
Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy
Mauro Vaccaro et al.
CHEMICAL COMMUNICATIONS (2009)
KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Christian G. Hartinger et al.
CHEMISTRY & BIODIVERSITY (2008)
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
